Medical - Instruments & Supplies
Compare Stocks
2 / 10Stock Comparison
HOLX vs ISRG
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Instruments & Supplies
HOLX vs ISRG — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Medical - Instruments & Supplies | Medical - Instruments & Supplies |
| Market Cap | $16.97B | $160.44B |
| Revenue (TTM) | $4.13B | $10.58B |
| Net Income (TTM) | $544M | $2.98B |
| Gross Margin | 52.8% | 66.3% |
| Operating Margin | 17.5% | 30.5% |
| Forward P/E | 17.2x | 43.7x |
| Total Debt | $2.63B | $303M |
| Cash & Equiv. | $1.96B | $3.37B |
HOLX vs ISRG — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | Apr 26 | Return |
|---|---|---|---|
| Hologic, Inc. (HOLX) | 100 | 143.4 | +43.4% |
| Intuitive Surgical,… (ISRG) | 100 | 238.4 | +138.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: HOLX vs ISRG
Each card shows where this stock fits in a portfolio — not just who wins on paper.
HOLX has the current edge in this matchup, primarily because of its strength in income & stability and sleep-well-at-night.
- beta 0.41
- Lower volatility, beta 0.41, Low D/E 52.0%, current ratio 3.75x
- Beta 0.41, current ratio 3.75x
ISRG is the clearest fit if your priority is growth exposure and long-term compounding.
- Rev growth 20.5%, EPS growth 22.6%, 3Y rev CAGR 17.4%
- 5.6% 10Y total return vs HOLX's 125.4%
- 20.5% revenue growth vs HOLX's 1.7%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 20.5% revenue growth vs HOLX's 1.7% | |
| Value | Lower P/E (17.2x vs 43.7x) | |
| Quality / Margins | 28.2% margin vs HOLX's 13.2% | |
| Stability / Safety | Beta 0.41 vs ISRG's 1.02 | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | +43.1% vs ISRG's -14.8% | |
| Efficiency (ROA) | 14.8% ROA vs HOLX's 5.9%, ROIC 15.0% vs 9.4% |
HOLX vs ISRG — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
HOLX vs ISRG — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
ISRG leads this category, winning 6 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ISRG is the larger business by revenue, generating $10.6B annually — 2.6x HOLX's $4.1B. ISRG is the more profitable business, keeping 28.2% of every revenue dollar as net income compared to HOLX's 13.2%. On growth, ISRG holds the edge at +23.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $4.1B | $10.6B |
| EBITDAEarnings before interest/tax | $974M | $3.8B |
| Net IncomeAfter-tax profit | $544M | $3.0B |
| Free Cash FlowCash after capex | $1000M | $2.8B |
| Gross MarginGross profit ÷ Revenue | +52.8% | +66.3% |
| Operating MarginEBIT ÷ Revenue | +17.5% | +30.5% |
| Net MarginNet income ÷ Revenue | +13.2% | +28.2% |
| FCF MarginFCF ÷ Revenue | +24.2% | +26.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | +2.5% | +23.0% |
| EPS Growth (YoY)Latest quarter vs prior year | -9.2% | +18.8% |
Valuation Metrics
HOLX leads this category, winning 6 of 6 comparable metrics.
Valuation Metrics
At 30.5x trailing earnings, HOLX trades at a 47% valuation discount to ISRG's 57.4x P/E. On an enterprise value basis, HOLX's 17.4x EV/EBITDA is more attractive than ISRG's 43.4x.
| Metric | ||
|---|---|---|
| Market CapShares × price | $17.0B | $160.4B |
| Enterprise ValueMkt cap + debt − cash | $17.6B | $157.4B |
| Trailing P/EPrice ÷ TTM EPS | 30.53x | 57.40x |
| Forward P/EPrice ÷ next-FY EPS est. | 17.21x | 43.67x |
| PEG RatioP/E ÷ EPS growth rate | — | 2.64x |
| EV / EBITDAEnterprise value multiple | 17.39x | 43.44x |
| Price / SalesMarket cap ÷ Revenue | 4.14x | 15.94x |
| Price / BookPrice ÷ Book value/share | 3.43x | 9.13x |
| Price / FCFMarket cap ÷ FCF | 18.44x | 64.42x |
Profitability & Efficiency
ISRG leads this category, winning 7 of 8 comparable metrics.
Profitability & Efficiency
ISRG delivers a 16.9% return on equity — every $100 of shareholder capital generates $17 in annual profit, vs $10 for HOLX. ISRG carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to HOLX's 0.52x. On the Piotroski fundamental quality scale (0–9), HOLX scores 7/9 vs ISRG's 6/9, reflecting strong financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | +10.4% | +16.9% |
| ROA (TTM)Return on assets | +5.9% | +14.8% |
| ROICReturn on invested capital | +9.4% | +15.0% |
| ROCEReturn on capital employed | +8.8% | +16.5% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 6 |
| Debt / EquityFinancial leverage | 0.52x | 0.02x |
| Net DebtTotal debt minus cash | $667M | -$3.1B |
| Cash & Equiv.Liquid assets | $2.0B | $3.4B |
| Total DebtShort + long-term debt | $2.6B | $303M |
| Interest CoverageEBIT ÷ Interest expense | 8.00x | — |
Total Returns (Dividends Reinvested)
ISRG leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ISRG five years ago would be worth $16,086 today (with dividends reinvested), compared to $11,665 for HOLX. Over the past 12 months, HOLX leads with a +43.1% total return vs ISRG's -14.8%. The 3-year compound annual growth rate (CAGR) favors ISRG at 14.2% vs HOLX's -2.9% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | +1.9% | -19.6% |
| 1-Year ReturnPast 12 months | +43.1% | -14.8% |
| 3-Year ReturnCumulative with dividends | -8.5% | +49.0% |
| 5-Year ReturnCumulative with dividends | +16.7% | +60.9% |
| 10-Year ReturnCumulative with dividends | +125.4% | +556.9% |
| CAGR (3Y)Annualised 3-year return | -2.9% | +14.2% |
Risk & Volatility
HOLX leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
HOLX is the less volatile stock with a 0.41 beta — it tends to amplify market swings less than ISRG's 1.02 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. HOLX currently trades 100.0% from its 52-week high vs ISRG's 74.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.41x | 1.02x |
| 52-Week HighHighest price in past year | $76.04 | $603.88 |
| 52-Week LowLowest price in past year | $51.90 | $427.84 |
| % of 52W HighCurrent price vs 52-week peak | +100.0% | +74.8% |
| RSI (14)Momentum oscillator 0–100 | 69.1 | 42.2 |
| Avg Volume (50D)Average daily shares traded | 9.7M | 1.8M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates HOLX as "Hold" and ISRG as "Buy". Consensus price targets imply 37.8% upside for ISRG (target: $623) vs 3.9% for HOLX (target: $79).
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy |
| Price TargetConsensus 12-month target | $79.00 | $622.60 |
| # AnalystsCovering analysts | 42 | 55 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +4.4% | +1.4% |
ISRG leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). HOLX leads in 2 (Valuation Metrics, Risk & Volatility).
HOLX vs ISRG: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is HOLX or ISRG a better buy right now?
For growth investors, Intuitive Surgical, Inc.
(ISRG) is the stronger pick with 20. 5% revenue growth year-over-year, versus 1. 7% for Hologic, Inc. (HOLX). Hologic, Inc. (HOLX) offers the better valuation at 30. 5x trailing P/E (17. 2x forward), making it the more compelling value choice. Analysts rate Intuitive Surgical, Inc. (ISRG) a "Buy" — based on 55 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — HOLX or ISRG?
On trailing P/E, Hologic, Inc.
(HOLX) is the cheapest at 30. 5x versus Intuitive Surgical, Inc. at 57. 4x. On forward P/E, Hologic, Inc. is actually cheaper at 17. 2x.
03Which is the better long-term investment — HOLX or ISRG?
Over the past 5 years, Intuitive Surgical, Inc.
(ISRG) delivered a total return of +60. 9%, compared to +16. 7% for Hologic, Inc. (HOLX). Over 10 years, the gap is even starker: ISRG returned +556. 9% versus HOLX's +125. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — HOLX or ISRG?
By beta (market sensitivity over 5 years), Hologic, Inc.
(HOLX) is the lower-risk stock at 0. 41β versus Intuitive Surgical, Inc. 's 1. 02β — meaning ISRG is approximately 148% more volatile than HOLX relative to the S&P 500. On balance sheet safety, Intuitive Surgical, Inc. (ISRG) carries a lower debt/equity ratio of 2% versus 52% for Hologic, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — HOLX or ISRG?
By revenue growth (latest reported year), Intuitive Surgical, Inc.
(ISRG) is pulling ahead at 20. 5% versus 1. 7% for Hologic, Inc. (HOLX). On earnings-per-share growth, the picture is similar: Intuitive Surgical, Inc. grew EPS 22. 6% year-over-year, compared to -25. 0% for Hologic, Inc.. Over a 3-year CAGR, ISRG leads at 17. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — HOLX or ISRG?
Intuitive Surgical, Inc.
(ISRG) is the more profitable company, earning 28. 4% net margin versus 13. 8% for Hologic, Inc. — meaning it keeps 28. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ISRG leads at 29. 3% versus 17. 4% for HOLX. At the gross margin level — before operating expenses — ISRG leads at 66. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is HOLX or ISRG more undervalued right now?
On forward earnings alone, Hologic, Inc.
(HOLX) trades at 17. 2x forward P/E versus 43. 7x for Intuitive Surgical, Inc. — 26. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ISRG: 37. 8% to $622. 60.
08Which pays a better dividend — HOLX or ISRG?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is HOLX or ISRG better for a retirement portfolio?
For long-horizon retirement investors, Hologic, Inc.
(HOLX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 41), +125. 4% 10Y return). Both have compounded well over 10 years (HOLX: +125. 4%, ISRG: +556. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between HOLX and ISRG?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: HOLX is a mid-cap quality compounder stock; ISRG is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.